"There's a growing focus on developing novel ADCs tailored to address unmet medical needs"

Nona Biosciences, a subsidiary of Hong Kong-listed Harbour BioMed is an emerging leader in Antibody-drug conjugates (ADCs).

- Ayesha Siddiqui

Nona excels in delivering comprehensive solutions from ‘Idea to IND.’ Their use of Harbour Mice technology and a team of seasoned experts enable them to offer integrated services in antibody discovery, from antigen preparation to pharmacological evaluation. Nona has forged partnerships with big pharma firms such as Pfizer and Moderna among others. Dr Jingsong Wang, Chairman of Nona Biosciences, shares more about the company, its plans and Asia’s ADC landscape. Edited excerpts:

Can you provide an overview of Nona Biosciences' integrated antibody discovery services?

Nona Biosciences is a global leading technology platform company committed to cutting-edge technology innovation and providing a total solution from ‘Idea to IND’ (I to I), ranging from target validation and antibody discovery through preclinical research.

The integrated antibody discovery services range from antigen preparation, animal immunisation, highly robust antibody screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice technology and the experienced therapeutic antibody discovery team.

Harbour Mice generates fully human monoclonal antibodies in a traditional two heavy and two light chain (H2L2) format, and a heavy chain only (HCAb) format. Integrating Harbour Mice with highly robust antibody screening platforms, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs.

Can you share the successful collaborations that you have undertaken and how these have contributed to the advancement of therapeutic antibody discovery?